Publicaciones en colaboración con investigadores/as de University of Milan (10)

2024

  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

2023

  1. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2021

  1. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

    ESMO Open

  2. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

  3. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 779-789

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

2017

  1. Dual modulation of MCL-1 and mTOR determines the response to sunitinib

    Journal of Clinical Investigation, Vol. 127, Núm. 1, pp. 153-168

2006

  1. Intraoperative radiation therapy. First part: Rationale and techniques

    Critical Reviews in Oncology/Hematology, Vol. 59, Núm. 2, pp. 106-115

  2. Intraoperative radiation therapy. Part 2. Clinical results

    Critical Reviews in Oncology/Hematology, Vol. 59, Núm. 2, pp. 116-127